Publicacións nas que colabora con Francisca Lago Paz (105)

2025

  1. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation

2024

  1. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction

    Biochemical Pharmacology, Vol. 230

2023

  1. Alpha-cardiac Actin Serum Expression Levels Detect Acute Cellular Rejection in Heart Transplant Patients

    Transplantation, Vol. 107, Núm. 2, pp. 466-474

  2. Combining Serum miR-144-3p and miR-652-3p as Potential Biomarkers for the Early Diagnosis and Stratification of Acute Cellular Rejection in Heart Transplantation Patients

    Transplantation, Vol. 107, Núm. 9, pp. 2064-2072

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  4. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Diagnostic value of serum miR-144-3p for the detection of acute cellular rejection in heart transplant patients

    Journal of Heart and Lung Transplantation, Vol. 41, Núm. 2, pp. 137-147

  2. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  3. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  4. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  5. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib

    Journal of Ethnopharmacology, Vol. 272

  2. Pharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity

    Molecules (Basel, Switzerland), Vol. 26, Núm. 4

  3. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2020

  1. Adipokines and inflammation: Focus on cardiovascular diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 20, pp. 1-34

  2. Levels of the novel endogenous antagonist of ghrelin receptor, liver-enriched antimicrobial peptide-2, in patients with rheumatoid arthritis

    Nutrients, Vol. 12, Núm. 4

2019

  1. Circulating Sphingosine-1-Phosphate as A Non-Invasive Biomarker of Heart Transplant Rejection

    Scientific reports, Vol. 9, Núm. 1, pp. 13880

  2. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

  3. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue

    Pharmacological Research, Vol. 144, pp. 51-65

  4. The altered expression of autophagy-related genes participates in heart failure: NRBP2 and CALCOCO2 are associated with left ventricular dysfunction parameters in human dilated cardiomyopathy

    PLoS ONE, Vol. 14, Núm. 4